Login / Signup

In Vivo Model Systems for Hepatitis B Virus Research.

Ana Maria Ortega-PrietoCatherine CherryHarry GunnMarcus Dorner
Published in: ACS infectious diseases (2019)
Hepatitis B virus (HBV) affects more than 257 million people globally, resulting in progressively worsening liver disease, manifesting as fibrosis, cirrhosis, and hepatocellular carcinoma. The exceptionally narrow species tropism of HBV restricts its natural hosts to humans and non-human primates, including chimpanzees, gorillas, gibbons, and orangutans. The unavailability of completely immunocompetent small-animal models has contributed to the lack of curative therapeutic interventions. Even though surrogates allow the study of closely related viruses, their host genetic backgrounds, immune responses, and molecular virology differ from those of HBV. Various different models, based on either pure murine or xenotransplantation systems, have been introduced over the past years, often making the choice of the optimal model for any given question challenging. Here, we offer a concise review of in vivo model systems employed to study HBV infection and steps in the HBV life cycle or pathogenesis.
Keyphrases
  • hepatitis b virus
  • liver failure
  • immune response
  • life cycle
  • endothelial cells
  • physical activity
  • gene expression
  • toll like receptor
  • decision making
  • prognostic factors
  • drug induced